CORT (Corcept Therapeutics) Retained Earnings: $611.6 Mil (As of Mar. 2026)


CORT Corcept Therapeutics Inc CORT
88 GF Score
Price $90.21
GF Value $62.56
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Corcept Therapeutics Retained Earnings?

Corcept Therapeutics CORT +1.96% 88 Retained Earnings is $611.6 Mil as of Mar. 2026. GuruFocus rates CORT with a GF Score™ of 88/100 and a GF Value™ of $62.56 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Corcept Therapeutics's retained earnings for the quarter that ended in Mar. 2026 was $611.6 Mil.

Corcept Therapeutics's quarterly retained earnings increased from Sep. 2025 ($619.1 Mil) to Dec. 2025 ($643.4 Mil) but then declined from Dec. 2025 ($643.4 Mil) to Mar. 2026 ($611.6 Mil).

Corcept Therapeutics's annual retained earnings increased from Dec. 2023 ($402.5 Mil) to Dec. 2024 ($543.7 Mil) and increased from Dec. 2024 ($543.7 Mil) to Dec. 2025 ($643.4 Mil).


Corcept Therapeutics  (NAS:CORT) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Corcept Therapeutics Retained Earnings Historical Data

* Premium members only.

The historical data trend for Corcept Therapeutics's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corcept Therapeutics Retained Earnings Chart

Corcept Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 194.97 296.39 402.53 543.74 643.39

Corcept Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 564.28 599.43 619.10 643.39 611.63
CORT
88GF Score
Corcept Therapeutics Inc CORT
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Corcept Therapeutics Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of $611.6 Mil mean?
Corcept Therapeutics (CORT) has a Retained Earnings of $611.6 Mil as of Mar. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Corcept Therapeutics and its competitors.
Is Corcept Therapeutics' Retained Earnings too high?
Corcept Therapeutics' current Retained Earnings is $611.6 Mil. Overall, Corcept Therapeutics has a GF Score™ of 88/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Corcept Therapeutics' Retained Earnings compare to PRAX and IBRX?
Corcept Therapeutics' Retained Earnings of $611.6 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Corcept Therapeutics and its competitors. Corcept Therapeutics's current Retained Earnings is $611.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corcept Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Corcept Therapeutics (CORT) is currently considered Significantly Overvalued. The stock's GF Value™ is $62.56, compared to a current price of $90.21 — trading 44.2% above its estimated fair value. The current Retained Earnings is $611.6 Mil. Corcept Therapeutics' overall GF Score™ is 88/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Corcept Therapeutics (CORT), the current Retained Earnings is $611.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Corcept Therapeutics (CORT) Overvalued in 2026?

Based on GuruFocus' analysis, Corcept Therapeutics stock appears to be overvalued. The current stock price of $90.21 is trading 44.2% above its estimated GF Value™ of $62.56. GuruFocus considers Corcept Therapeutics to be Significantly Overvalued.

Key valuation signals for CORT:

  • Retained Earnings: $611.6 Mil
  • GF Value™: $62.56 vs. price of $90.21 (44.2% above fair value)
  • GF Score™: 88/100 with 8 warning signs

No single metric tells the full story. See the CORT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Corcept Therapeutics Business Description

Address 101 Redwood Shores Parkway, Redwood City, CA, USA, 94065
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
88GF Score

Get the complete analysis for CORT

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$90.21
Price
$62.56
GF Value